Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
It is very uncertain whether comparison 13: SSRIs changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 2: anticonvulsants/GABAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Relapse · adults with SAnD
Comparison 13: SSRIs probably leads to lower relapse rate ‐ no. relapsed compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
Comparison 13: SSRIs may leads to higher dropouts due to adverse events (acute phase) compared with placebo (low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD
1 finding from 1 review
Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term) Post‐treatment: 1‐4 months · adults with SAnD
Comparison 13: SSRIs may leads to higher clinical Global Impressions scale change item (CGI‐I): no. of… compared with placebo (low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults with SAnD
It is very uncertain whether comparison 13: SSRIs changes dropouts due to adverse events (long term) Post‐treatment: 1‐4 months compared with placebo (very low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
Comparison 14: GW876008 showed no clear difference in global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
Comparison 14: GW876008 showed no clear difference in dropouts due to adverse events (acute phase) compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
It is very uncertain whether comparison 15: NK1 receptor antagonist GR205171 changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
Comparison 3: anticonvulsant levetiracetam showed no clear difference in global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (moderate certainty).
1 finding from 1 review
Depressive symptoms · patients with depression
2 findings from 1 review